SBP GROUP (01177): Latest research results for TQ-A3334 "TLR7 agonist" and Bepirovirsen "ASO" will be presented at the 2026 AASLD
China Biopharmaceutical (01177) announced that a clinical study result of TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) for the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented as an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
SBP GROUP (01177) announced that a clinical study result for TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) at the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented as an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
Related Articles
Autek China Inc. (300595.SZ) subsidiary plans to invest 120 million yuan in Hengyi Medical.
Shenzhen JPT Opto-Electronics (688025.SH)'s application for issuing A-shares to specific targets has passed the review by the Shanghai Stock Exchange.
Preview of US Stock Market | U.S. stock index futures mixed as chip and optical communication stocks fall broadly in premarket trading; key U.S. September CPI data looms
Autek China Inc. (300595.SZ) subsidiary plans to invest 120 million yuan in Hengyi Medical.
Shenzhen JPT Opto-Electronics (688025.SH)'s application for issuing A-shares to specific targets has passed the review by the Shanghai Stock Exchange.
Preview of US Stock Market | U.S. stock index futures mixed as chip and optical communication stocks fall broadly in premarket trading; key U.S. September CPI data looms
